Cargando…

Clinical Considerations for Immunoparesis in Multiple Myeloma

SIMPLE SUMMARY: Immunoparesis in multiple myeloma is defined as the suppression of one or more of the uninvolved immunoglobulins, AKA, polyclonal immunoglobulin. The extent of immunoparesis is an independent prognostic factor in patients with newly diagnosed multiple myeloma. Myeloma patients with s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chahin, Michael, Branham, Zachery, Fox, Ashley, Leurinda, Christian, Keruakous, Amany R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104750/ https://www.ncbi.nlm.nih.gov/pubmed/35565407 http://dx.doi.org/10.3390/cancers14092278

Ejemplares similares

Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma
por: Chakraborty, Rajshekhar, et al.
Publicado: (2020)

Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma
por: Huang, Weimin, et al.
Publicado: (2021)

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
por: Sørrig, Rasmus, et al.
Publicado: (2017)

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
por: Heaney, Jennifer L. J., et al.
Publicado: (2018)

Pain Management in Oncology Patients Amidst the Opioid Epidemic: How To Minimize Non-Medical Opioid Use
por: Chahin, Michael, et al.
Publicado: (2021)

Lifestyle considerations in multiple myeloma
por: Shapiro, Yael N., et al.
Publicado: (2021)

Case report: Hyperosmolar hyperglycemic syndrome secondary to PEG-asparaginase-induced hypertriglyceridemia and pancreatitis
por: Mudd, Todd William, et al.
Publicado: (2023)

Barriers driving health care disparities in utilization of age-appropriate screening
por: Keruakous, Amany R., et al.
Publicado: (2023)

Low-pathogenicity mycoplasma species induce immunoparesis and are highly prevalent amongst patients with ventilator-associated pneumonia
por: Nolan, TJ, et al.
Publicado: (2015)

P28: RESPONSE AND VACCINATION STATUS OR LACK OF IMMUNOPARESIS ARE ASSOCIATED WITH BETTER OUTCOME FOLLOWING COVID-19 INFECTION AMONG PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE ON 110 PATIENTS
por: Seval, Guldane Cengiz, et al.
Publicado: (2022)

Insights into Clinical Features and Outcomes of Adrenal Cortical Carcinosarcoma
por: Branham, Zachery, et al.
Publicado: (2022)

Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients
por: Wang, Jing, et al.
Publicado: (2015)

High Output Heart Failure in Multiple Myeloma: Pathogenetic Considerations
por: Carlisi, Melania, et al.
Publicado: (2022)

Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody
por: Pan, Darren, et al.
Publicado: (2023)

Research Staff Perspectives on Cancer Clinical Trials and Barriers to Recruitment: A Qualitative Research
por: Keruakous, Amany R, et al.
Publicado: (2021)

End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma
por: Hoering, Antje, et al.
Publicado: (2017)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

A Push to Consider Mantle Cell Lymphoma in Adults with Leukemia/Lymphoma with Blastoid Morphology
por: Arinze, Nkechi, et al.
Publicado: (2023)

Antithyroid drugs induced agranulocytosis and multiple myeloma: case report and general considerations
por: Dănciulescu Miulescu, R, et al.
Publicado: (2013)

Multiple myeloma
por: Collins, Conor D.
Publicado: (2010)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
por: Merin, Noah M., et al.
Publicado: (2014)

Potential Clinical Application of Genomics in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2018)

New developments in the treatment of multiple myeloma – clinical utility of daratumumab
por: McEllistrim, Cian, et al.
Publicado: (2017)

Curability of Multiple Myeloma
por: Alexanian, Raymond, et al.
Publicado: (2012)

Targeted Therapies for Multiple Myeloma
por: Leow, Christopher Chang-Yew, et al.
Publicado: (2021)

Severe Pneumonia Caused by Legionella pneumophila: Differential Diagnosis and Therapeutic Considerations
por: Chahin, Abdullah, et al.
Publicado: (2017)

Elotuzumab for the treatment of multiple myeloma
por: Wang, Yucai, et al.
Publicado: (2016)

Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors
por: Gengenbach, Laura, et al.
Publicado: (2021)

Multiple myeloma/hypercalcemia
por: Oyajobi, Babatunde O
Publicado: (2007)

Immunotherapy for Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2019)

Integrins in multiple myeloma
por: Hosen, Naoki
Publicado: (2020)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
por: Bernstein, Zachary S., et al.
Publicado: (2022)

Interpretation of cytogenetic results in multiple myeloma for clinical practice
por: Rajan, A M, et al.
Publicado: (2015)

Recent updates on CAR T clinical trials for multiple myeloma
por: Lin, Quande, et al.
Publicado: (2019)

Clonal Evolution of Multiple Myeloma—Clinical and Diagnostic Implications
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2021)

Imaging findings of extraosseous multiple myeloma
por: Patlas, Michael, et al.
Publicado: (2015)

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
por: Bhatt, Parva, et al.
Publicado: (2023)

Multiple Myeloma and Diabetes
por: Issa, Zeinab A., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_abfa6u0cd5mn4r3p3dff1ea2h8